The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
Abstract
Background In randomised controlled trials, fixed-dose combination treatments (or polypills) have been shown to reduce a composite of cardiovascular disease outcomes in primary prevention. However, whether or not aspirin should be included, effects on specific outcomes, and effects in key subgroups are unknown.Methods We did an individual participant data meta-analysis of large randomised controlled trials (each with ≥1000 participants and ≥2 years of follow-up) of a fixed-dose combination treatment strategy versus control in a primary cardiovascular disease prevention population. We included trials that evaluated a fixed-dose combination strategy of at least two blood pressure lowering agents plus a statin (with or without aspirin), compared with a control strategy (either placebo or usual care). The primary outcome was time to first occurrence of a composite of cardiovascular death, myocardial infarction, stroke, or arterial revascularisation. Additional outcomes included individual cardiovascular outcomes and death from any cause. Outcomes were also evaluated in groups stratified by the inclusion of aspirin in the fixed-dose treatment strategy, and effect sizes were estimated in prespecified subgroups based on risk factors. Kaplan-Meier survival curves and Cox proportional hazard regression models were used to compare strategies.Findings Three large randomised trials were included in the analysis (TIPS-3, HOPE-3, and PolyIran), with a total of 18 162 participants. Mean age was 63·0 years (SD 7·1), and 9038 (49·8%) participants were female. Estimated 10-year cardiovascular disease risk for the population was 17·7% (8·7). During a median follow-up of 5 years, the primary outcome occurred in 276 (3·0%) participants in the fixed-dose combination strategy group compared with 445 (4·9%) in the control group (hazard ratio 0·62, 95% CI 0·53-0·73, p<0·0001). Reductions were also observed for the separate components of the primary outcome: myocardial infarction (0·52, 0·38-0·70), revascularisation (0·54, 0·36-0·80), stroke (0·59, 0·45-0·78), and cardiovascular death (0·65, 0·52-0·81). Significant reductions in the primary outcome and its components were observed in the analyses of fixed-dose combination strategies with and without aspirin, with greater reductions for strategies including aspirin. Treatment effects were similar at different lipid and blood pressure levels, and in the presence or absence of diabetes, smoking, or obesity. Gastrointestinal bleeding was uncommon but slightly more frequent in the fixed-dose combination strategy with aspirin group versus control (19 [0·4%] vs 11 [0·2%], p=0·15). The frequencies of haemorrhagic stroke (10 [0·2%] vs 15 [0·3%]), fatal bleeding (two [<0·1%] vs four [0·1%]), and peptic ulcer disease (32 [0·7%] vs 34 [0·8%]) were low and did not differ significantly between groups. Dizziness was more common with fixed-dose combination treatment (1060 [11·7%] vs 834 [9·2%], p<0·0001).Interpretation Fixed-dose combination treatment strategies substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularisation, and cardiovascular death in primary cardiovascular disease prevention. These benefits are consistent irrespective of cardiometabolic risk factors.Funding Population Health Research Institute.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistently, a recent IPD meta-analysis of 18 162 patients with multiple CV risk factors and no previous ASCVD (risk 1.7%/ year) showed a significant benefit of low-dose ASA, incremental to lipid-and BP-lowering drugs.This was also observed in a diabetes subgroup (Supplementary data online, Table S11).293”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [293]
Citations
Cites
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Self-citationGeneral Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Chow, C. K. (2013) · JAMA · doi:10.1001/jama.2013.184182 · Cited by 1,991
A strategy to reduce cardiovascular disease by more than 80%
Wald, N. J., & Law, M. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1419 · Cited by 1,568
Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors
Joseph, P., Leong, D., McKee, M., Anand, S. S., Schwalm, J.-D., Teo, K., Mente, A., & Yusuf, S. (2017) · Circulation Research · doi:10.1161/circresaha.117.308903 · Cited by 1,073
Self-citationDagenais, G. R., Leong, D. P., Rangarajan, S., Lanas, F., Lopez-Jaramillo, P., Gupta, R., Diaz, R., Avezum, A., Oliveira, G. B. F., Wielgosz, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32007-0 · Cited by 651
Self-citationZheng, S. L., & Roddick, A. J. (2019) · JAMA · doi:10.1001/jama.2018.20578 · Cited by 577
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Feigin, V. L., Owolabi, M. O., Feigin, V. L., Abd-Allah, F., Akinyemi, R. O., Bhattacharjee, N. V., Brainin, M., Cao, J., Caso, V., Dalton, B., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00277-6 · Cited by 804
Self-citationPolypill strategy in secondary cardiovascular prevention
Castellano, J. M., Pocock, S. J., Bhatt, D. L., Quesada, A. J., Owen, R., Fernandez-Ortiz, A., Sanchez, P. L., Marin Ortuño, F., Vazquez Rodriguez, J. M., Domingo-Fernández, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208275 · Cited by 334
Self-citation
Metadata
- Authors
- Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., Avezum, A., Zhu, J., Liu, L., Sliwa, K., Gamra, H., Bangdiwala, S. I., Teo, K., Diaz, R., Dans, A., Lopez-Jaramillo, P., Prabhakaran, D., Castellano, J. M., Fuster, V., Rodgers, A., Huffman, M. D., Bosch, J., Dagenais, G. R., Malekzadeh, R., & Yusuf, S.
- Affiliations
- Population Health Research Institute (CA)
- Golestan University of Medical Sciences (IR)
- St. John's Research Institute (IN)
- St.John's Medical College Hospital (IN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Cape Town (ZA)
- University of Monastir (TN)
- University of the Philippines Manila (PH)
- Public Health Foundation of India (IN)
- Instituto de Salud Carlos III (ES)
- The George Institute for Global Health (AU)
- Northwestern University (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Shariati Hospital (IR)
- Corresponding author
- Yusuf, Salim
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 398
- Issue
- 10306
- Pages
- 1133-1146
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3196464088
- Cited by
- 151
- References
- 24
- Citations by year
- 2026: 8 · 2025: 24 · 2024: 34 · 2023: 42 · 2022: 34 · 2021: 9
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- fixed-dose combination, polypill, aspirin, primary prevention, cardiovascular disease, statins, blood pressure lowering agents, cardiovascular mortality, myocardial infarction, stroke, revascularization, subgroup analysis, cardiovascular risk stratification
- MeSH terms
- Aspirin, Blood Pressure, Cardiovascular Diseases, Drug Therapy, Combination, Female, Gastrointestinal Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Primary Prevention, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01827-4
- The paper
- Joseph, P., Roshandel, G., Gao, P., Pais, P., Lonn, E., Xavier, D., Avezum, A., Zhu, J., Liu, L., Sliwa, K., Gamra, H., Bangdiwala, S. I., Teo, K., Diaz, R., Dans, A., Lopez-Jaramillo, P., Prabhakaran, D., Castellano, J. M., Fuster, V., . . . Yusuf, S. (2021). Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(21)01827-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.